These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 19056165

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D, Feustel C, Persson de Geeter C, Stehr M, Radmayr C, Sillén U, Strugala G.
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [Abstract] [Full Text] [Related]

  • 3. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Lazzeri M.
    Eur Urol; 2009 Mar; 55(3):737-8. PubMed ID: 18502027
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
    Grigoleit U, Mürtz G, Laschke S, Schuldt M, Goepel M, Kramer G, Stöhrer M.
    Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y, Yamaguchi O, Imidafenacin Study Group.
    Int J Urol; 2009 May; 16(5):499-506. PubMed ID: 19389083
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy and safety of propiverine on improvement of symptoms and QOL for female patients with wet overactive bladder].
    Kato M, Matsukawa Y, Kato K, Kondo A, Yamada S, Hattori R, Gotoh M.
    Hinyokika Kiyo; 2008 Mar; 54(3):165-71. PubMed ID: 18411770
    [Abstract] [Full Text] [Related]

  • 11. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
    Martínez-García R, Abadías M, Arañó P, Perales L, Ruíz JL, Sust M, Conejero J, ESCLIN 006/00 study group.
    Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V, 1032 Study Group.
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [Abstract] [Full Text] [Related]

  • 13. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD, Lucente V, Vapnek J, Smith N.
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [Abstract] [Full Text] [Related]

  • 14. [Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence].
    Noguchi K, Masuda M, Noguchi S, Kubota Y, Hosaka M, Senga Y, Sano K, Miyai K, Kanno H, Kitami K, Fujinami K, Miura T, Kondo I, Kawasaki C, Moriyama M, Hara Y, Ida T, Fukuoka H, Nakagawa J, Kitajima N, Fukuda M, Satomi Y, Takahashi T, Yamaguchi T, Shiozaki H.
    Hinyokika Kiyo; 1998 Sep; 44(9):687-93. PubMed ID: 9805679
    [Abstract] [Full Text] [Related]

  • 15. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A, Okayama Urological Research Group.
    Scand J Urol Nephrol; 2009 Sep; 43(4):307-14. PubMed ID: 19396723
    [Abstract] [Full Text] [Related]

  • 16. Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62.
    Staskin DR, Oefelein MG.
    Eur Urol; 2009 Mar; 55(3):e49-50; author reply e51. PubMed ID: 18829154
    [No Abstract] [Full Text] [Related]

  • 17. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
    Madersbacher H, Mürtz G, Alloussi S, Domurath B, Henne T, Körner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G.
    BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Schaefer W.
    Int J Urol; 2007 Jul; 14(7):670; author reply 670-1. PubMed ID: 17645621
    [No Abstract] [Full Text] [Related]

  • 19. Editorial comment from Dr Dmochowski to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
    Dmochowski RR.
    Int J Urol; 2011 May; 18(5):374. PubMed ID: 21355895
    [No Abstract] [Full Text] [Related]

  • 20. Editorial comment from Dr Sekido to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
    Sekido N.
    Int J Urol; 2011 May; 18(5):373-4. PubMed ID: 21382097
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.